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Late outgrowth endothelial progenitor cells (LO-EPC) possess a high proliferative potential, differentiate into vascular endothelial
cells (EC), and form networks, suggesting they play a role in vascular repair. However, due to their scarcity in the circulation there
is a requirement for ex vivo expansion before they could provide a practical cell therapy and it is currently unclear if they would
home and engraft to an injury site. Using an in vitro flow system we studied LO-EPC under simulated injury conditions including
EC activation, ischaemia, disrupted EC integrity, and exposed basement membrane. Perfused LO-EPC adhered to discontinuous
EC paracellularly at junctional regions between adjacent cells under shear stress 0.7 dyn/cm2. The interaction was not adhesion
molecule-dependent and not enhanced by EC activation. LO-EPC expressed high levels of the VE-Cadherin which may explain
these findings. Ischaemia reperfusion injury decreased the interaction with LO-EPC due to cell retraction. LO-EPC interacted
with exposed extracellular matrix (ECM) proteins, fibronectin and vitronectin. The interaction was mediated by integrins 𝛼5𝛽3,
𝛼v𝛽1, and 𝛼v𝛽3.This study has demonstrated that an injured local environment presents sufficient adhesive signals to capture flow
perfused LO-EPC in vitro and that LO-EPC have properties consistent with their potential role in vascular repair.
1. Introduction
Endothelial cells (EC) play an important role in regulating
vascular homeostasis, modulating permeability, maintaining
vascular tone, and responding to various stimuli by the
production of bioactive substances [1]. Loss of endothelial
integrity may cause a variety of deleterious consequences
including acute events such as thrombus formation and pre-
disposing to chronic pathology including transplant vascu-
lopathy and atherosclerosis leading to complications such as
coronary heart disease, stroke, and diabetes [2–5]. Endothe-
lial integrity depends on a balance between the extent of
endothelial cell injury and the capacity for endogenous repair.
In healthy individuals, neighbouringmature endothelial cells
can replicate locally and replace damaged cells [3]. However
if injurious stimuli are prolonged and/or repeated or there is
a large area of damage, endogenous repair may be inadequate
[6] and require additional repair mechanisms.
Endothelial progenitor cells (EPC) could provide an alter-
native mechanism for maintenance and repair of damaged
endothelium in vivo. Two types of EPC with distinct prop-
erties have been identified, early outgrowth EPC (EO-EPC)
and late outgrowth EPC (LO-EPC) [7–11]. Early outgrowth
EPC are short-lived cells (<2 weeks) and do not differentiate
into EC in vivo but can restore endothelial function and
enhance angiogenesis after tissue ischaemia via a paracrine
effect [8, 12, 13]. However, they are a heterogeneous pop-
ulation of hematopoietic cells including monocyte-derived
immune cells [12, 14, 15]; delivering large numbers of ex
vivo expanded autologous EO-EPC might risk exacerbating
immune response. LO-EPC, by contrast, are a homogeneous
endothelial-like progenitor cell population that possess a high
proliferative potential, differentiate into vascular endothelial
cells, and form networks in vitro and in vivo [10, 16, 17]. We
and others have shown that LO-EPCmorphology and angio-
genic function is preserved in patients with cardiovascular
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risk factors and patients with end stage renal failure [16, 18].
Their proliferation, differentiation, and tube forming ability
are increased by laminar shear stress [19–22] suggesting that
they may contribute to autologous vascular repair. However
LO-EPC are not abundant in the circulation [7, 23]. To use
them therapeutically LO-EPC would need to be expanded ex
vivo to high concentrations before being delivered back into
the circulation. The fate of LO-EPC after delivery including
their ability to home to and engraft at a site of injury is not
known.
Vascular damage is characterised by endothelial cell
activation and dysfunction that may progress to detachment
leading to loss of endothelial integrity [3, 24]. Endothelial
cell damage markers including endothelial microparticles
derived from activated or apoptotic cells and whole endothe-
lial cells can be detected in the circulation [25]. Once the
endothelial monolayer is disrupted, the basement membrane
is exposed to blood flow. This layer provides the primary
physical support for endothelial cells and is composed of col-
lagen type IV, collage type I, fibronectin, vitronectin, laminin,
and several proteoglycans (including heparin sulphate pro-
teoglycan) [26]. These local changes may influence LO-EPC
homing and engraftment. In this study, we investigated the
dynamic interaction of LO-EPC with normal endothelial
cells, activated endothelial cells or those undergoing simu-
lated ischaemia reperfusion injury, and different extracellular
matrix (ECM) proteins. Understanding the interaction of
LO-EPC under simulated injury conditions in vitro and the
mechanism of LO-EPC capture from flow will provide us
with a critical view on the practicality of using LO-EPC for
endogenous repair.
2. Materials and Methods
2.1. Cell Culture. This study had full ethical approval from the
institutional review board of the Clinical School, University
of Cambridge, and written informed consent was obtained
from all volunteers. Late outgrowth EPC were isolated as
previously described [16]. Briefly, mononuclear cells (MNC)
were isolated from 40mls venous peripheral blood by
density-gradient centrifugation with Ficoll-paque-1.077 (GE
Healthcare, UK).Themononuclear cells were plated in a cul-
ture flask coatedwith type I collagen (BD,UK) and cultured at
37∘Cunder 5%CO
2
atmosphere in endothelial basal medium
(EBM) supplemented with SingleQuots (Lonza) and 20%
Hyclone fetal calf serum (Fisher Scientific,UK).Nonadherent
cells were removed after 3 days in culture and the medium
was changed on alternate days. Colonies of LO-EPC appeared
after 2 to 3 weeks in culture and exhibited typical cobblestone
morphology. Once individual colony cell number reached
500–1000, the cells were passaged into a new collagen-coated
flask. Subsequently cells were passaged at a 1 : 3 ratio into
noncoated flasks. The medium was changed every other day.
LO-EPC from passages 4–6 were used.
Human abdominal aorta endothelial cells (HAEC) were
purchased fromPromoCell, Germany.The cells were cultured
in complete endothelial growth medium with 5% fetal calf
serum (PromoCell). The medium was changed every other
day. Cells from passages 3–6 were used.
2.2. Interaction of LO-EPC and HAEC under In Vitro Shear
Flow. 3 × 104 HAEC were plated directly on Ibidi 𝜇-Slide VI
0.4 Luer slides (Thistle Scientific LTD, UK) 48 hours before
the experiments. HAEC were either left untreated, or treated
with 0.05 ng/mL TNF𝛼 for 4 hours, or subjected to ischaemia
for 4 hours followed by reperfusion overnight, before being
connected to the flow system. The flow system was set up as
previously described [27, 28]. Briefly, to perfuse the cells in
the flow system, one end of the Ibidi slide was attached by
silicon rubber tubing to an electronic valve, which allowed
smooth switching between the LO-EPC suspension andwash
buffer (1% BSA in DPBS, Sigma, UK) held in vertical syringe
barrels, and the other end of the Ibidi slide was attached by
silicon rubber tubing to a Harvard syringe pump (Harvard
Apparatus, UK). The flow rate of 0.4mL/min was pump-
controlled. The equivalent shear stress (𝜏) exerted on Ibidi
𝜇-Slide VI 0.4 Luer slide surface at a flow rate of 0.4mL/min
(Φ) was 0.7 dyn/cm2, which was calculated from the equation
“𝜏 = 𝜂176.1Φ”. 𝜂 (dynamical viscosity) was 0.01 dyn⋅s/cm2.
LO-EPC were labelled with Dil-Ac-LDL to distinguish them
from HAEC after adhesion. After insertion of the Ibidi slide
into the flow system, the slide was washed for 2min with 1%
BSA in DPBS (perfusion buffer). A total of 4 × 105 labelled
LO-EPC in 1.5mL perfusion buffer were then perfused
at a shear stress of 0.7 dyn/cm2 for 4min. An additional
2min wash was applied to remove nonadherent cells. The
interaction of LO-EPC with endothelial cells was observed
and recorded during the LO-EPC perfusion, and the images
were retained.The number of adherent LO-EPCwas counted
and expressed as adherent cells per square millimetre. Video-
microscopic recordings weremade and analyzed offline using
computerized image analysis software (Image ProPlus and
Image J).The interactions of LO-EPCwith HAECwere easily
observed on the video and individual cell motion including
rolling, tethering, transient adhesion, and firm arrest was
recorded. The flow experiments were conducted at 37∘C
within a Perspex chamber.
2.3. Interaction of LO-EPC and ECM under In Vitro Shear
Flow. 100 𝜇g/𝜇L of collagen IV (BD, UK), collagen I (BD,
UK), fibronectin (Sigma, UK), vitronectin (Invitrogen, UK),
or laminin (Sigma, UK) was preplated to Ibidi 𝜇-Slide VI
0.4 Luer slides for 1 hour at 37∘C. The Ibidi slide was then
connected to the flow system as described above. The slide
was washed for 2min with 1% BSA in DPBS. A total of 4 ×
105 LO-EPC in 1.5mL were perfused at a shear stress of
0.7 dyn/cm2 for 4min. An additional 2min wash was applied
to remove the nonadherent cells. Cells were subsequently
fixed with 4% paraformaldehyde for 15min at room temper-
ature, washed twice with PBS, and stained with Hoechst dye
(1 𝜇g/mL) for 30min. The number of adherent LO-EPC was
imaged, counted, and expressed as adherent cells per square
millimetre.
2.4. Static Interaction of LO-EPC with ECM. 100 𝜇g/𝜇L of
collagen IV, collagen I, fibronectin, vitronectin, or laminin
was preplated to Ibidi 𝜇-Slide VI 0.4 Luer slides for 1 hour
at 37∘C before rinsing twice with DPBS. 2 × 104 LO-EPCwere
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seeded on each ECM-treated Ibidi slide and incubated at
37∘C for 45min. After washing twice with DPBS, cells were
fixed with 4% paraformaldehyde for 15 minutes at room
temperature and stained with Hoechst for 30min. The total
number of adherent cells was imaged, counted, and expressed
as adherent cells per square millimetre.
2.5. Flow Cytometric Analysis of Cell Surface Markers. To
study TNF𝛼 mediated HAEC activation, control HAEC and
HAEC treated with 0.05 ng/𝜇L TNF𝛼 (R&D System, UK), for
4 hours at 37∘C, were collected in 100 𝜇L 1% bovine serum
albumin (BSA, Sigma) in PBS and incubated with fluorescein
conjugated anti-human E-selectin antibodies (R&D System),
APC conjugated anti-human ICAM-1 (BD), and PE/Cy5
conjugated anti-human VCAM-1 (Bio Legend, UK), together
with the respective isotype control antibodies. Forward-side
scatter plotswere used to exclude dead cells. Data analysis was
performed using CELL Quest software (BD) and FlowJo.
The expression of VE-Cadherin in LO-EPC and HAEC
was quantified by flow cytometry using a FITC conju-
gated antibody against human VE-Cadherin (Abcam, UK),
together with its corresponding isotype.
2.6. Immunofluorescence Staining. VE-Cadherin expression
was visualized by immunofluorescence staining. Control
HAEC and HAEC treated with ischaemia reperfusion injury
were fixed for 15min in 4% paraformaldehyde. Cells were
then blocked for 30min in 3% (w/v) BSA in TBS at pH 7.4
(blocking buffer). FITC conjugated VE-Cadherin antibodies
(Abcam, UK) were diluted 1 : 50 in blocking buffer and
incubated with cells at 4∘C overnight.
2.7. Cell Staining of Dil-Acetylated-Low Density Lipoprotein
(Dil-Ac-LDL). Both endothelial cells and LO-EPC can take
up Dil-Ac-LDL. To label LO-EPC with Dil-Ac-LDL, LO-EPC
were incubated with 10 𝜇g/mL of Dil-Ac-LDL (Molecular
Probes, Invitrogen) for 1 hour at 37∘C and then washed twice
with PBS. Labelled LO-EPC were distinguished from HAEC
after adhesion.
2.8. VE-Cadherin Blocking Studies. Purified mouse antibody
against human VE-Cadherin was used to block the surface
expression of VE-Cadherin in HAEC (clone: BV9, Biolegend,
UK). 3 × 104 HAEC were incubated with 50 𝜇g/mL of anti-
body for 1 hour at 37∘C before being connected to the flow
system as described above. The cells were washed for 2min
with 1%BSA inDPBS prior to perfusion, with a total of 4× 105
LO-EPC in 1.5mL of 1% BSA in DPBS.
2.9. Ischaemia Reperfusion Injury. Ischaemia reperfusion
injury was simulated by anoxic (O
2
< 1% and CO
2
> 5%) and
acidotic conditions with glucose and pyruvate deprivation
as described previously [29]. LO-EPC were incubated with a
minimal volume of ischaemia solution (118mMNaCl, 24mM
NaHCO
3
















lactate, and 16mMKCl, pH 6.2) under hypoxia in an anaero-
bic bag (BDH), at 37∘C for 4 h. Cells were then transferred
to a 37∘C incubator with 5% CO
2
with additional complete
culture medium for reperfusion overnight.
2.10. Integrin Blocking Studies. 1.5mL of 4 × 105 LO-EPC
was incubated with 10 𝜇g/mL anti-ITG 𝛼5𝛽1 (Millipore, UK),
anti-ITG 𝛼V𝛽3 (Millipore, UK), and anti-ITG 𝛼v𝛽1 (Bioss,
Antibodies-online.com) or no antibodies (control) for 30
minutes at 37∘C with gentle rotation. LO-EPC were then
perfused onto fibronectin pretreated Ibidi slides under a shear
stress of 0.7 dyn/cm2. After perfusion, the slides were washed
for an additional 2min to remove nonadherent cells. Adher-
ent cells were then fixed with 4% paraformaldehyde and
stained with Hoechst. The cells were imaged, counted, and
expressed as adherent cells per square millimetre.
2.11. Live Cell Image Acquisition and Analysis. Live cell
imaging of the interaction of LO-EPC with HAEC or ECM
was performed using a digital imaging system coupled to an
inverted microscope under flow conditions. The camera was
set up to observe the top view of the rolling of LO-EPC on
endothelial cells or ECM. The images were acquired though
Image Pro software. The images were taken from a represen-
tative field of view every 30 seconds for 5min from the start
of LO-EPC perfusion. The sequence of events including LO-
EPC rolling, tethering, and binding was recorded. The total
number of adherent LO-EPC was stained with Hoechst or
Dil-Ac-LDL and determined by counting the total adherent
cells in 3–6 fields of view. The rolling velocity was observed
but no specific measurements were recorded in this study.
2.12. Statistical Analysis. All values are expressed as mean ±
SE from at least three separate experiments. Within each
independent experiment, at least duplicate measurements
were performed. One way ANOVA with Newman Keuls post
hoc test was used to determine significance for all exper-
iments. A probability value of 𝑝 < 0.05 was considered
statistically significant and is indicated by ∗, and 𝑝 < 0.01
is indicated by ∗∗.
3. Results
3.1. Interaction of LO-EPC with Human Abdominal Aorta
Endothelial Cells under Flow. The interaction of LO-EPC
with a human abdominal aortic endothelial cell (HAEC)
monolayer was assessed under 0.7 dyn/cm2 shear stress at
37∘C. Figure 1(a) shows LO-EPC adhere to a subconfluent
HAEC monolayer (3 × 104) at gaps between adjacent HAEC
paracellularly rather than adhering to superficial (luminal)
surface of the HAEC. Interaction did not occur on a com-
pletely confluent HAEC monolayer (6 × 104) (Figure 1(b)).
The number of cells adhering to complete confluent and sub-
confluentHAECwas 3.25±0.38 and 21.46± 1.81/mm2, respec-
tively. Dilution of the seeded HAEC to 1 × 104 to increase the
intercellular spacing between HAEC decreased the adhesion
of LO-EPC to HAEC (data not shown), suggesting that
LO-EPC preferentially form adjacent contacts with HAEC.
Similar rolling velocity was observed regardless of HAEC
confluence. The adherent LO-EPC appeared as round cells
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Figure 1: Representative phase-contrast live cell images of interaction of LO-EPC with 3 × 104 subconfluent (a) and 6 × 104 confluent (b)
HAEC monolayers under shear stress 0.7 dyn/cm2. 4 × 105 LO-EPC were perfused for 4min. Arrows indicated adherent LO-EPC which
only adhered paracellularly at junctional regions of discontinuity between two cells in subconfluent HAEC monolayer. Scale bar 30𝜇m.
After adhesion LO-EPC spread and establish cell-cell interaction (c). LO-EPC were labelled with DiI-Ac-LDL shown red. Scale bar 60𝜇m.
VE-Cadherin staining revealed the formation of lateral junction between LO-EPC and HAEC (d). LO-EPC were labelled with DiI-Ac-LDL
shown red and VE-Cadherin expression shown green.
initially, but they could withstand the shear forces, spread
rapidly after firm adhesion, and start to establish cell-cell
connections under 0.7 dyn/cm2 shear stress (Figure 1(c)).
Immunofluorescence staining of VE-Cadherin in adherent
LO-EPC revealed adhesion junction formation between LO-
EPC and HAEC (Figure 1(d)), while Claudin-5 (tight junc-
tion protein) and PECAM showed more diffuse staining in
adherent LO-EPC (data not shown), suggestingVE-Cadherin
promotes a homotypic type of recognition between LO-EPC
and HAEC. Adhesion of LO-EPC did not disrupt the HAEC
morphology andmonolayer structure and no transmigration
of LO-EPC was observed.This was in contrast to monocytes,
which interacted only by binding superficially to a confluent
HAEC layer and then transmigrating (data not shown).
3.2. The Interaction of LO-EPC with HAECWas Not Adhesion
Molecule-Dependent under Flow. TNF𝛼 (0.05 ng/mL) was
used to induce HAEC activation to investigate whether this
enhanced the interaction with LO-EPC. HAEC activation
was characterised by increased expression of cell surface
adhesion molecules E-selectin, ICAM-1, and VCAM-1 in
HAEC (Figure 2(a)). Activation did not increase the inter-
action with LO-EPC under 0.7 dyn/cm2 shear stress (Fig-
ure 2(b)) and there was no difference seen in rolling velocity,
suggesting that adhesion molecules did not mediate LO-
EPC rolling or adhesion to HAEC under flow conditions.
This contrasted with monocytes in which the interaction
increased when HAEC were activated. When 106 monocytes
were perfused the number of adherent monocytes increased
from 6.01 ± 0.67 cells per millimetre square in untreated
HAEC to 45.74 ± 4.03 cells per millimetre square in activated
HAEC (𝑝 < 0.01) under 0.7 dyn/cm2 shear stress.
3.3. Vascular Endothelial- (VE-) Cadherin Mediates the Inter-
action of LO-EPC with HAEC under Flow. VE-Cadherin
is an endothelium specific adhesion protein prominently
located at junctions between endothelial cells suggesting it
may play a role in initiating the interaction of LO-EPC
with HAEC. We showed that LO-EPC had higher expression
levels of VE-Cadherin compared to HAEC (Figure 3(d)).
Higher expression of VE-Cadherin could contribute to LO-
EPC adherence to HAEC paracellularly.
To investigate the involvement of VE-Cadherin in the
interaction of LO-EPC with HAEC under dynamic flow, an
antibody against VE-Cadherin was used to block the surface
expression of VE-Cadherin (Figures 3(a) and 3(b)). Blocking
VE-Cadherin in HAEC reduced the interaction of LO-EPC
with HAEC significantly (Figure 3(c)), without significantly

































































Figure 2: Interaction of LO-EPCwith activatedHAEC. Surface expression of adhesionmolecules inHAEC after stimulation with 0.05 ng/mL
TNF𝛼 (a). Surface expressions of E-selectin, ICAM-1, and VCAM-1 were quantified using flow cytometry. The graph shows relative Mean
Fluorescence Intensity (MFI) normalised to untreated cells and represents the mean ± SE of three experiments. ∗∗𝑝 < 0.01. Activation of
HAEC did not increase the interaction with LO-EPC (b). 4 × 105 LO-EPC were perfused to 3 × 104 HAEC for 4min and the data represented
as mean ± SE of three experiments.
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Figure 3: Representative microscopic images of VE-Cadherin expression in control HAEC (a) and HAEC incubated with anti-VE-Cadherin
antibody for 1 hour at 37∘C (b). Scale bar 20 𝜇m. Effect of VE-Cadherin on dynamic interaction of LO-EPC with HAEC. 4 × 105 LO-EPC
were perfused (c). The data was represented as mean ± SE of three experiments. ∗∗𝑝 < 0.01. Representative flow cytometric histograms
illustrating VE-Cadherin expression in LO-EPC and HAEC (d). The lined histogram represents VE-Cadherin expression in HAEC and the
filled histogram represents VE-Cadherin expression in LO-EPC.
changing the rolling velocity (observation only), confirming
the role ofVE-Cadherin in LO-EPCadhesion toHAECunder
0.7 dyn/cm2 shear stress.
3.4. Decreased Interaction of LO-EPC with HAEC after
IschaemiaReperfusion Injury under Flow. HAEC treatedwith
simulated ischaemia reperfusion in vitro under flow showed
decreased interaction with LO-EPC compared to normal
HAEC (Figure 4(a)). Four hours of ischaemia followed by
reperfusion caused HAEC retraction and detachment, also
demonstrated by significantly more floating cells in the
supernatant compared to untreated control HAEC. There
was no significant difference in VE-Cadherin expression
between control HAEC and HAEC with ischaemia reper-
fusion injury (Figures 4(b)–4(d)). This suggests that the
decreased interaction between LO-EPC and HAEC after
ischaemia reperfusion injury may be due to cell retraction
and increased intercellular space between HAEC rather than
being VE-Cadherin related.
3.5. Interaction of LO-EPC with Extracellular Matrix Proteins.
When injured endothelial cells retract and/or detach, inter-
stitial basal membrane is exposed. Endothelial basal mem-
branes are comprised of several extracellular matrix (ECM)
proteins, including collagen IV, collagen I, fibronectin, vit-
ronectin, and laminin. We compared the adhesion of LO-
EPC to different ECM. There was no significant difference
in LO-EPC binding to collagen IV, collagen I, fibronectin,
and vitronectin under static conditions (Figure 5(a)). Under
0.7 dyn/cm2 shear stress, however, LO-EPC bind to different
ECMwith different strengths, with a higher adhesive strength
for fibronectin and vitronectin (Figure 5(b)). There were no
signs of toxicity of these substrates on LO-EPC. In addition
LO-EPC adhere more avidly to fibronectin and vitronectin
than they do to HAEC (Figure 4(a)).
Differences in rolling velocity were observed when exam-
ining the motion of LO-EPC interaction with ECM under
the microscope. The rolling of LO-EPC on fibronectin and
vitronectin coated surfaces was slower (data not shown),

































Figure 4: Dynamic interaction of LO-EPC with control HAEC and HAEC with ischaemia reperfusion injury (a). The data represented
as mean ± SE of three experiments. ∗∗𝑝 < 0.01. Representative flow cytometric histograms of VE-Cadherin expression in control HAEC
and HAEC with ischaemia reperfusion injury (b). The filled histogram represents VE-Cadherin expression in control HAEC and the
unfilled histogram represents VE-Cadherin in HAECwith ischaemia reperfusion injury. Representative microscopic images of VE-Cadherin



























































































Figure 5: LO-EPC adhesion to various extracellular matrix proteins under static and flow conditions. 2 × 104 of LO-EPC were plated to
Ibidi 𝜇-Slide VI 0.4 Luer slides for 45min to study the static adhesion of LO-EPC to various ECM (a). Dynamic adhesion of LO-EPC to
various extracellular matrix proteins under 0.7 dyn/cm2 shear stress (b). 4 × 105 EPC were perfused into Ibidi 𝜇-Slide VI 0.4 Luer slides
coated with 100 𝜇g/mL collagen IV, collagen I, fibronectin, vitronectin, and laminin, respectively. The data was represented as mean ± SE of
three experiments. ∗∗𝑝 < 0.01 compared to fibronectin.










Figure 6: LO-EPC (4 × 105) were perfused over fibronectin-coated Ibidi slides and time lapse imaging was used to visualise and record LO-
EPC adhesion. Representative still images show three adherent cells after initial capture (a, b) after 4min of perfusion (0.7 dyn/cm2). Scale
bar represents 30 𝜇m. Adherent LO-EPC form lateral adhesion junction (c). LO-EPC labelled with DiI-Ac-LDL shown red and VE-Cadherin
expression shown green. Scale bar 20𝜇m. 24 hours after adhesion to fibronectin, LO-EPC spread and proliferate (d). Scale bar represents
60 𝜇m.The adherent LO-EPC effectively cover a fibronectin-coated surface (e). Scale bar represents 110𝜇m.
suggesting that fibronectin and vitronectin influenced both
rolling and adhesion phases of interaction with LO-EPC.
Figure 6(a) shows that, under a shear stress of 0.7 dyn/
cm2, LO-EPC readily attach and spread on a fibronectin
coated surface. Rolling LO-EPC appeared as round cells
initially, but rapidly spread, formed cell-cell connections
upon firm adhesion, and withstood a total of 10min perfu-
sion under flow (Figures 6(a) and 6(b)). LO-EPC displayed
coordinated adhesion behaviour under flow with sequential
events of rolling along the surface for short distances and
episodes of transient tethering prior to firm adherence.
Immunofluorescence staining of VE-Cadherin in adherent
LO-EPC confirmed the formation of lateral junctions (Fig-
ure 6(c)). 24 hours after adhesion, LO-EPC had proliferated
(Figure 6(d)) and a large surface areawas covered by adherent
LO-EPC (Figure 6(e)).
3.6. Exposed Fibronectin Enhanced the Cell-Cell Interac-
tion between LO-EPC and HAEC. Interaction of LO-EPC
with HAEC that had undergone ischaemia reperfusion was
increased when HAEC had been seeded on to fibronectin
(Figures 7(a) and 4(a)). There was no significant difference









































Figure 7: The influence of fibronectin on the dynamic interaction of LO-EPC with control HAEC and HAEC with ischaemia reperfusion
injury under 0.7 dyn/cm2 shear stress. 3× 104HAECwere plated into Ibidi𝜇-SlideVI 0.4 Luer slideswhich had been precoatedwith 100 𝜇g/mL
fibronectin. The data represent a mean ± SE of three experiments. LO-EPC adhesion to fibronectin was integrin dependent (b). LO-EPC
binding to fibronectin was blocked by antibodies against integrin 𝛼5𝛽1, integrin 𝛼v𝛽1, and integrin 𝛼v𝛽3. The data represent the mean ± SE
of three experiments. ∗∗𝑝 < 0.01 compared to the control (no blocking antibodies).
between the dynamic interactions of LO-EPC with control
HAEC and HAEC with ischaemia reperfusion injury (Fig-
ure 7(a)), suggesting fibronectin could promote the cell-cell
interaction of LO-EPC with a retracted or discontinuous
HAEC in order to aid in the reformation of the endothelial
cell monolayer.
3.7. Integrins Mediate Adhesion of LO-EPC on Extracellular
Matrix Proteins under Flow. We have shown previously that
there is differential integrin gene expression in LO-EPC, with
higher expression of integrin monomers 𝛼v, 𝛼5, 𝛽1, and 𝛽3
and higher cell surface expression of integrin heterodimers
𝛼5𝛽3, 𝛼v𝛽1, and 𝛼v𝛽3 [16]. Using blocking antibodies against
integrins 𝛼5𝛽3, 𝛼v𝛽1, and 𝛼v𝛽3, the interaction of LO-
EPC with fibronectin was significantly decreased. The data
suggested that the interaction between LO-EPC and ECM
wasmediated largely by these three integrins 𝛼5𝛽3, 𝛼v𝛽1, and
𝛼v𝛽3 (Figure 7(b)).
4. Discussion
Adhesion of LO-EPC to injury sites involves both cell-cell and
cell-matrix interactions. Enabling direct interaction between
endothelial cells and ECM is likely critical for LO-EPC
homing and performing vascular repair at the injury site.The
most extensively studied cell-cell interaction under dynamic
flow is the interaction of leukocytes with endothelial cells [27,
30, 31]. Studies on the dynamic interaction of early outgrowth
EPC with endothelial cells showed a strong resemblance
to that of leukocyte interactions with activated endothelial
cells; they share some common features of a coordinated
sequence of multistep adhesive events including an initial
phase of rolling and final firm adhesion [32, 33]. The initial
phase of leukocyte rolling in vivo is mediated by P-selectin
and firm adhesion is mediated by E-selectin, ICAM-1, and
VCAM-1 [32, 33]. Until now there has been no information
on the dynamic interaction of LO-EPC with endothelial
cells. Using an in vitro flow system to simulate physical
conditions of blood circulation in vivo, we showed that LO-
EPCdid not interact with confluent ECunder flowbut readily
adhered and spread where there were discontinuities in the
EC monolayer. The interaction occurred paracellularly at
gaps in the intercellular junctions between EC and was not
critically adhesion molecule-dependent since upregulating
the cell surface adhesion molecules E-selectin, ICAM-1, and
VCAM-1 in HAEC did not alter the interaction of LO-EPC
with EC under flow. The adhesion mechanism is distinct
and in contrast to the interaction of early outgrowth EPC
[33], monocytes [31], and mesenchymal stem cells (MSC)
[34] in which the interactions with endothelial cell were all
adhesion molecule-dependent. One possible explanation for
the apparent different adhesion mechanism used by LO-EPC
may be the integrin expression profile of LO-EPC. LO-EPC
show low expression of integrins 𝛼L𝛽2, 𝛼M𝛽2, 𝛼X𝛽2, and
𝛼D𝛽2 [16], which are responsible for binding to vascular
ligands such as ICAM-1, ICAM-2, and VCAM-1 [35, 36]. LO-
EPC also have lower expression of integrin 𝛼4𝛽1, whereas
MSC engage VLA-4 (integrin 𝛼4𝛽1)/VCAM-1 to mediate
firm adhesion on EC [34]. Different cells may use different
adhesion mechanisms depending on the respective adherent
properties as demonstrated previously in the interaction of
tumour cells andendothelial cells. Cells fromdifferent tumour
types interact with the endothelial surface using different
mechanisms depending on adhesion molecules expressed on
the tumour and endothelial cell surface [37].
The interaction of LO-EPCwithHAEC occurred paracel-
lularly suggesting that cell-cell contact on lateral surfacesmay
play a role in initiating this interaction. Vascular endothelial-
(VE-) Cadherin is a strictly endothelial specific adhesion
junction protein, prominently localised at endothelial cell
lateral borders and mediates homotypic cell-cell adhesion
[38–40]. “Homophilic interactions” betweenLO-EPCandEC
suggest that VE-Cadherin may mediate initial adhesion of
LO-EPC to endothelial cells. VE-Cadherin, CD31, andCD146
are typically associated with a more mature endothelial
phenotype; however we showed that LO-EPC had a higher
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level of VE-Cadherin compared to mature endothelial cells
(HAEC), which may be significant in ensuring that LO-EPC
resist tractive flow forces. The adhesion junction formation
observed in the adherent LO-EPC with HAEC confirmed
that the adhesion of LO-EPC with HAEC was at least
partly mediated by VE-Cadherin. Interactions between VE-
Cadherin activate the cellular cascade signalling pathways
further strengthening the cadherin interaction [41]. Indeed,
blocking VE-Cadherin in the endothelial cells reduced their
interaction with LO-EPC interaction under dynamic flow. In
addition, VE-Cadherin regulates various cellular processes
such as cell proliferation and modulates vascular endothelial
growth factor receptor functions as well as being involved
in VE-Cadherin-mediated contact inhibition of cell growth
[42, 43]; therefore LO-EPCwould fulfil nearly every function
required by reparative cells. A similar interaction pattern was
also observed previously in the interaction of blood-borne
tumour cells with endothelial cells. The preferred tumour
cells interactions prior to tumour cell extravasation occur at
sites near to endothelial intercellular junctions [44]. Although
VE-Cadherin is a strictly EC specific adhesion molecule
it is also expressed by aggressive melanoma tumours [45].
Development of long-term firm adhesions depends on the
collaborative interactions of several adhesion proteins includ-
ing tight junction protein and PECAM. Ayalon et al. showed
that there were spatial and temporal relationships between
VE-Cadherin and PECAM-1 in regulating endothelial cell-
cell interaction [46]. Cadherins became organized on the
cell surface much earlier than PECAM-1 and served as the
nucleation sites for subsequent and adjacent assembly of
PECAM-1 adhesions [46]. The reciprocal role of these junc-
tional proteins in regulating stable junction organization and
biological activity in the adherent LO-EPC remains to be
clarified.
When endothelial cells are subjected to ischaemia reper-
fusion injury, the dynamic interaction of LO-EPC with EC
was decreased. Koto et al. reported that hypoxia could disrupt
the barrier function of neural blood vessels through changes
in the expression of adhesion junction protein claudin-5
in endothelial cells [47]. However, our data showed that
ischaemia reperfusion injury did not significantly influence
VE-Cadherin expression in EC, suggesting that decreased
interaction was unlikely to be due to disrupted VE-Cadherin
function.This was in agreement with Chen et al. who showed
that 4 hours of ischaemia did not cause significant changes in
mRNA expression of VE-cadherin and claudin-5 in endothe-
lial cells in the lung [48]. The decreased interaction we
observed was likely due to an increase in the size and number
of intercellular spaces caused by cellular retraction under
these conditions. This is consistent with our observation that
increasing the cell spacing of a monolayer also decreased LO-
EPC interaction.
The extracellular matrix (ECM) beneath the endothe-
lium is a highly organized complex network of collagens,
fibronectin, vitronectin, laminin as well as proteoglycans,
glycoproteins, and bound growth factors. They form a thin
sheet-like matrix to create varying degrees of tissue tensile
strength to preserve the function and integrity of blood ves-
sels [22, 49–51]. When endothelial cells are damaged, ECM
components will be exposed on the luminal surface. So far
there has been little study of adhesion of LO-EPC to ECM
under dynamic flow. Angelos et al. showed that LO-EPC
could interact with fibronectin and the number of LO-EPC
adhering to a fibronectin coated surfacewas influenced by the
perfused cell density and shear stress [52]. In this study, we
compared LO-EPC adhesion strength to different ECM and
demonstrated that LO-EPC are highly adhesive to fibronectin
and vitronectin but less so on collagen IV, collagen I, and
laminin under a shear stress of 0.7 dyn/cm2. Different ECM
interact with cells via different cell surface integrin receptors
[53, 54]. We showed that the interaction of LO-EPC with
fibronectin was strongly dependent on integrins 𝛼5𝛽1, 𝛼V𝛽1,
and 𝛼V𝛽3. The involvement of integrin 𝛼5𝛽1 in LO-EPC
with matrix protein is in agreement with other published
works [22, 52] in which increased adhesion of LO-EPC to
fibronectin was generated by LO-EPC producing multiple
contacts of 𝛼5𝛽1 with a fibronectin-coated surface and the
contact area growing during the first 20 minutes of attach-
ment [52]. Previously we showed that there was higher
gene expression of integrin subunits 𝛼5, 𝛼v, 𝛽1, and 𝛽3,
moderate expression of 𝛼6 and 𝛼E, and low level expression
of other integrin subunits, and that integrins 𝛼5𝛽1, 𝛼V𝛽3,
and 𝛼V𝛽3 have higher cell surface expression in LO-EPC
[16], the receptors for fibronectin (integrins 𝛼5𝛽1, 𝛼V𝛽1,
and 𝛼V𝛽3) [55] and vitronectin (integrin 𝛼V𝛽3) [56]. The
receptor for collagen IV and collagen I (integrins 𝛼1𝛽1 and
𝛼2𝛽1) [57, 58] and laminin (integrins 𝛼3𝛽1, 𝛼6𝛽1, 𝛼7𝛽1, and
𝛼6𝛽4) [58] were expressed at lower levels in LO-EPC. The
constitution of endothelial basal membranes varies between
different vascular beds and fibronectin and vitronectin are
not normally involved in maintaining tissue structure and
are found at lower levels in quiescent vessels [59, 60]. Both
fibronectin and vitronectin are present in the bloodstream
[61] with serum concentrations of 300 𝜇g/mL and 200–
300 𝜇g/mL, respectively [62, 63]. When an endothelial cell
monolayer is damaged, the cells leak into the injured area and
are rapidly deposited in injured tissue, becoming a prominent
constituent of the endothelial basement membrane, and
provide an adhesive scaffold for the recruitment of cells [49,
62, 63].Thehigher local concentrations of fibronectin and vit-
ronectin after injury and the higher binding strength with
LO-EPCmake the injury site a strong target for capturing LO-
EPC homing to an injury site.
Although in this study we examined the interaction of
LO-EPC with HAEC and ECM separately, these two pro-
cesses are closely linked and occur concomitantly, especially
in the initial phase of vascular injury. Endothelial cells and
the supportingmatrix exist in a state of “dynamic reciprocity”
to serve and regulate each other. ECM not only provides a
substrate for cell attachment and spreading, contact guidance
for cell migration, and a scaffold for building tissues but also
serves as a reservoir for growth factors [64]. EC are primarily
responsible for the synthesis and deposition of these ECM
[64]. We found that fibronectin and vitronectin provided
superior adhesion for LO-EPC compared to HAEC. Adhe-
sion to ECMhelped LO-EPC to establish junctional adhesion
with HAEC as shown by EC with ischaemia reperfusion
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injury causing decreased dynamic interaction with LO-EPC
which was restored when EC were seeded on fibronectin.
It was reported that mature endothelial cells increase
deposition of collagen IV, fibronectin, and laminin under
hypoxic condition which may contribute to the complex
interplay between endothelial cells and ECM [50]. EPC
deposited collagen IV, fibronectin, and laminin to a greater
extent than mature EC [65].Therefore, using autologous LO-
EPC therapeutically could amplify these benefits and enhance
endogenous repair.
Limitations of This Study. (1) In this study 0.7 dyn/cm2 shear
stress was used to investigate the dynamic interaction of LO-
EPC with endothelial cells and ECM. Angelos et al. showed
that the number of adherent LO-EPC/cm2 exhibited a bipha-
sic response with the optimal shear stress for late outgrowth
EPC binding to fibronectin at 1 dyn/cm2 [52], a biphasic
response similar to both neutrophils and monocytes binding
to the endotheliumunder flow [66, 67].The adhesive strength
under flow not only depends on adhesive signals, but also
depends on shear stress. Higher shear stress could interfere
with the binding strength by increased rolling velocity or
might help with binding if modelling of microvillus defor-
mation is accurate [68]. Future studies will investigate the
influence of different shear stresses on interaction of LO-EPC
with endothelial cells and ECM.
(2) The model used in this study was a simplified one.
In vivo, exposed endothelial basal membrane is not only a
target for LO-EPC; but it will also attract platelets and other
immune cells. Platelets aggregate immediately after endothe-
lial denudation and adhere to ECM by platelet-specific
integrin 𝛼IIb𝛽3 [60]. Activated platelets play a role not only
in thrombosis but also in inflammation, immune responses,
and atherosclerotic disease [69]. Recently it was reported that
activated platelets could also support adhesion andmigration
of circulating progenitor cells [70]. Platelet-coated ECMmay
represent an attractive adhesive surface promoting arrest of
circulating CD34+ progenitor cells in vitro as well as in vivo
[71]. Whether platelets and other inflammatory cytokines
encourage or prevent LO-EPC interaction with endothelial
cells and ECM under flow perfusion will be investigated in
future experiments.
5. Conclusion
In conclusion, we have demonstrated that discontinuous
endothelial monolayer and exposed ECM were sufficient
adhesive signals to capture LO-EPC from flow perfusion in
vitro and that LO-EPC demonstrate appropriate properties to
effect vascular repair. Further studies are needed to examine
whether these adhesive signals are effective under different
shear stresses and strong enough to capture LO-EPC from
blood circulation in vivo.
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